uniQure N.V. - Ordinary Shares (OQ:QURE)

Feb 28, 2024 07:05 am ET
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the fourth quarter and full year 2023 and highlighted recent progress...
Dec 19, 2023 07:05 am ET
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated interim data including up to 30 months of follow-up from 39 patients enrolled in the...
Dec 11, 2023 06:30 pm ET
CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Li
HEMGENIX® is the first and only gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia B and to show sustained efficacy and safety at three years post-treatmentLong-term data continues to show a one-time infusion of HEMGENIX offers elevated and sustained factor IX activity levels for years and significantly reduces the rate of annual bleeds versus factor IX prophylaxis with a favorable safety profileAt three years post-treatment with HEMGENIX, 94% of patients remained free of continuous prophylactic treatmentKING OF PRUSSIA, Pa., Dec. 11, 2023 /P
Dec 08, 2023 07:05 am ET
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement equity awards to newly hired employees. The company granted equity...
Nov 29, 2023 07:05 am ET
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND)...
Nov 07, 2023 07:05 am ET
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2023 and highlighted recent progress across its...
Oct 27, 2023 10:00 am ET
CSL and uniQure Win 2023 Prix Galien USA Award
HEMGENIX®, the first and only FDA-approved gene therapy for adults with hemophilia B, wins for Best Product for Rare/Orphan Diseases
Oct 26, 2023 02:14 pm ET
Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B
CSL's HEMGENIX® is a one-time, single dose treatment for adults with hemophilia B who require routine prophylaxis
Oct 24, 2023 07:05 am ET
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be delivered at the European...
Oct 05, 2023 07:05 am ET
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced a strategic reorganization that will significantly reduce operating expenses while supporting...
Oct 02, 2023 07:05 am ET
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement equity awards to newly hired employees. The Company granted equity...
Sep 05, 2023 07:05 am ET
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND)...
Aug 01, 2023 07:05 am ET
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2023 and highlighted recent progress across its...
Jun 26, 2023 07:11 am ET
uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Walid Abi-Saab, M.D., as Chief Medical Officer, effective immediately. He will...
Jun 23, 2023 11:45 am ET
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 23, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or "the Company") (NASDAQ:QURE) for violations of the securities laws.
Jun 22, 2023 08:45 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (“uniQure” or “the Company”) (NASDAQ:
Jun 22, 2023 07:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm
LOS ANGELES, CA / ACCESSIWRE / June 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or "the Company") (NASDAQ:QURE) for violations of the securities laws.
Jun 21, 2023 01:19 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (“uniQure” or “the Company”) (NASDAQ:
Jun 21, 2023 09:31 am ET
Thinking about buying stock in bluebird bio, Uniqure, Terawulf, Metaworks Platforms, or Nikola Corp?
NEW YORK, June 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLUE, QURE, WULF, MWRK, and NKLA.
Jun 21, 2023 09:31 am ET
Thinking about buying stock in Eightco Holdings, Uniqure, Atento, Red Cat Holdings, or Opendoor Technologies?
NEW YORK, June 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCTO, QURE, ATTO, RCAT, and OPEN.
Jun 21, 2023 07:05 am ET
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced promising interim data, including up to 24 months of follow-up, from 26 patients enrolled in the...
Jun 20, 2023 07:05 am ET
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced the achievement of a $100 million milestone associated with the first commercial sale of HEMGENIX® in...
Jun 20, 2023 07:00 am ET
CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B
HEMGENIX®, the first and only FDA approved gene therapy for hemophilia B, has been proven to elevate and sustain factor IX levels for years, significantly reduce the rate of annual bleeds versus standard of care, and reduce or eliminate the need for prophylactic treatment in 94% of patients (51 out of 54) after a one-time infusionKING OF PRUSSIA, Pa., June 20, 2023 /PRNewswire/ -- Global biotechnology leader CSL Behring today announced that the first patient has received U.S. Food and Drug Administration (FDA) approved HEMGENIX® (etranacogene dezaparvovec-drlb) for hemophilia B in the United
Jun 16, 2023 07:05 am ET
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement equity awards to Jeannette Potts, the Company’s newly hired Chief Legal...
May 15, 2023 07:05 am ET
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced it has entered into a definitive agreement to sell a portion of the royalty rights due to uniQure...
May 09, 2023 07:05 am ET
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2023 and highlighted recent progress across its...
May 02, 2023 04:40 pm ET
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be delivered at the American...
May 02, 2023 07:05 am ET
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 38 employees as a material inducement to commencing...
Mar 13, 2023 07:05 am ET
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 31 employees as a material inducement to commencing...
Mar 02, 2023 07:05 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in March
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Cowen Annual...
Feb 27, 2023 07:05 am ET
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for 2022 and highlighted recent progress across its business. “We had a...
Feb 23, 2023 08:05 am ET
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that its partner, global biotechnology leader CSL (ASX: CSL) today announced the publication in the New...
Feb 21, 2023 07:05 am ET
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that its partner, global biotechnology leader CSL (ASX: CSL), has received conditional marketing...
Jan 31, 2023 07:05 am ET
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, and Apic Bio, an innovative gene therapy company developing novel treatment options for patients with rare...
Dec 20, 2022 07:05 am ET
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to employees as a material inducement to commencing their...
Dec 16, 2022 07:15 am ET
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that its partner, global biotechnology leader CSL (ASX: CSL), has received a positive opinion...
Dec 10, 2022 09:00 am ET
CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatm
Long-term data from the pivotal HOPE-B study show a one-time infusion of HEMGENIX generated elevated and sustained mean factor IX levels and reduced the rate of annual bleeding 24-month results reinforced safety of treatment, with no serious treatment-related adverse effects related to HEMGENIX infusion HEMGENIX, recently approved by the U.S. Food and Drug Administration, is the first and only gene therapy for the treatment of certain adults living with hemophilia BKING OF PRUSSIA, Pa., Dec. 10, 2022 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) today announced the presentation
Nov 29, 2022 11:00 am ET
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, hosted a virtual investor event focused on AMT-260, an AAV gene therapy for refractory temporal lobe epilepsy...
Nov 22, 2022 04:40 pm ET
uniQure announces FDA approval of first gene therapy for adults with hemophilia B
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that its partner, global biotechnology leader CSL (ASX: CSL), has received approval from the U.S. Food...
Nov 22, 2022 02:59 pm ET
U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B
-  This historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy and generates elevated and sustained factor IX levels for years after a one-time infusion
Nov 17, 2022 07:05 am ET
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will host a Virtual Research & Development Event on Tuesday, November 29, 2022 from 8:30...
Nov 02, 2022 07:05 am ET
uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2022 and highlighted recent progress across its...
Oct 11, 2022 07:05 am ET
uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that eight data presentations will be delivered at the European Society of Gene and Cell Therapy...
Oct 03, 2022 07:05 am ET
uniQure to Participate in Upcoming Industry Conferences in October
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Chardan’s 6th...
Sep 06, 2022 07:05 am ET
uniQure to Participate in Upcoming Industry Conferences in September
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Citi’s 17th...
Aug 08, 2022 07:05 am ET
uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2022 and highlighted recent progress across its...
Jun 23, 2022 07:05 am ET
uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase...
Jun 22, 2022 04:34 pm ET
CORRECTION -- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
In a release issued under the same headline earlier today by uniQure N.V. (NASDAQ: QURE), please note that all the numbers have been updated. The corrected release follows: uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing...
Jun 22, 2022 07:05 am ET
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 32 newly hired employees as a material inducement to...
May 24, 2022 08:00 am ET
uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics...
May 11, 2022 07:05 am ET
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 32 newly hired employees as a material inducement to...
May 02, 2022 04:45 pm ET
uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that six data presentations, including one oral presentation, will be delivered at the American...
May 02, 2022 07:05 am ET
uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2022 and highlighted recent progress across its...
Mar 28, 2022 02:13 am ET
European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B
Marketing Authorization Application (MAA) for etranacogene dezaparvovec will be reviewed under accelerated assessment and has the potential to be the first gene therapy for patients living with hemophilia B
Mar 21, 2022 07:05 am ET
uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of patient enrollment in the first two cohorts of its randomized, double-blinded,...
Mar 02, 2022 07:00 am ET
Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer
Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LBT4) systems are implicated, today...
Feb 25, 2022 07:05 am ET
uniQure Announces 2021 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for 2021 and highlighted recent progress across its business. “We made...
Feb 07, 2022 07:05 am ET
uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of...
Feb 04, 2022 09:20 am ET
Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022
KING OF PRUSSIA, Pa., Feb. 4, 2022 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced positive long-term results from the Phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational adeno-associated virus five (AAV5)-based gene therapy for people living with hemophilia B, a life-threatening bleeding disorder. Following a single infusion of etranacogene dezaparvovec, participants experienced a stable and durable increase in mean Factor IX (FIX) activity and hemostatic protection at 18 months. The final data, from the largest gene t
Dec 16, 2021 07:00 am ET
uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced initial observations on the first four patients enrolled in the lower-dose cohort of its ongoing...
Dec 15, 2021 06:33 am ET
CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec for European Patients Living with Hemophilia B
KING OF PRUSSIA, Pa., Dec. 15, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the Committee for Medicinal Products for Human Use (CHMP), the chief scientific body of the European Medicines Agency (EMA) accepted its request for an accelerated assessment of the etranacogene dezaparvovec Marketing Authorisation Application (MAA). Etranacogene dezaparvovec (also known as EtranaDez), currently being studied in the Phase 3 HOPE-B clinical trial, is an investigational gene therapy for people living with hemophilia B, a life-threatening bleeding disorder.
Dec 09, 2021 07:05 am ET
uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
CSL Behring, a global biotherapeutics leader, and uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that etranacogene dezaparvovec, an...
Nov 02, 2021 07:05 am ET
uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the positive recommendation by the independent Data Safety Monitoring Board (DSMB) following a...
Nov 01, 2021 07:05 am ET
uniQure to Participate in Upcoming Industry Conferences in November
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: The 28th Annual...
Oct 25, 2021 07:05 am ET
uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2021 and highlighted recent progress across its...
Oct 21, 2021 09:30 am ET
uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors. Ms. Jacques, who will serve on the...
Oct 19, 2021 07:05 am ET
uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation, will be delivered at the European...
Sep 30, 2021 07:05 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in October
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Chardan’s 5th...
Sep 07, 2021 08:30 am ET
Thinking about buying stock in Adaptimmune Therapeutics, Ziopharm Oncology, Uniqure NV, GlycoMimetics, or AbCellera Biologics?
NEW YORK, Sept. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, ZIOP, QURE, GLYC, and ABCL.
Sep 07, 2021 07:05 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in September
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Citi’s 16th...
Sep 03, 2021 06:55 pm ET
Match Group, Ceridian HCM and Brown & Brown Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK, Sept. 3, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following index adjustments to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 to ensure each index is more representative of its market capitalization range. The changes will be effective prior to the open of trading on Monday, September 20, 2021 to coincide with the quarterly rebalance:
Aug 30, 2021 07:05 am ET
uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntingto
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that two additional patient procedures have been completed in the second, higher-dose cohort in...
Jul 26, 2021 07:05 am ET
uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2021 and highlighted recent progress across its...
Jul 02, 2021 09:00 am ET
uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that eight data presentations, of which three are oral presentations, will be delivered at the...
Jun 22, 2021 11:31 am ET
uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory Update
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced positive 52-week clinical data on all patients from its pivotal, Phase III HOPE-B gene therapy...
Jun 22, 2021 11:31 am ET
uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced it has entered into a definitive agreement to acquire Corlieve Therapeutics and its lead program,...
Jun 16, 2021 07:05 am ET
uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first two patient procedures have been completed in the higher dose, second cohort of...
Jun 02, 2021 07:34 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in June
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences:...
May 27, 2021 07:05 am ET
uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing the Phase I/II clinical trial...
May 13, 2021 07:00 am ET
uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, yesterday presented 26-week clinical data from the pivotal, Phase III HOPE-B gene therapy trial of etranacogene...
May 10, 2021 07:05 am ET
uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2021 and highlighted recent progress across its...
May 06, 2021 07:00 am ET
uniQure announces closing of commercialization and license agreement with CSL Behring
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for the...
May 03, 2021 07:05 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in May
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences: 7th...
Apr 28, 2021 07:05 am ET
uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that five data presentations, of which two are oral presentations, will be delivered at the...
Apr 26, 2021 07:05 am ET
uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced today that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Company’s...
Apr 08, 2021 07:05 am ET
uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the Brain
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that three manuscripts on preclinical data from its gene therapy candidate AMT-130 in...
Apr 05, 2021 07:05 am ET
uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of patient enrollment in the first dose cohort of a randomized, double-blinded,...
Apr 01, 2021 07:05 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in April
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences: Virtual...
Mar 29, 2021 07:05 am ET
uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced today the results of a comprehensive investigation into the case of hepatocellular carcinoma (HCC)...
Mar 01, 2021 07:05 am ET
uniQure Announces 2020 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for 2020 and highlighted recent progress across its business. “Despite...
Feb 26, 2021 07:05 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in March
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences: Cowen...
Feb 08, 2021 07:05 am ET
uniQure Announces Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing the Phase I/II clinical trial...
Feb 01, 2021 07:05 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in February
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences: 14th...
Dec 23, 2020 03:20 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE
NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Dec 21, 2020 07:05 am ET
uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that its hemophilia B gene therapy program, including the pivotal, Phase III HOPE-B study, has...
Dec 08, 2020 07:00 am ET
uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematolo
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the late-breaking presentation of initial data from its pivotal, Phase III HOPE-B gene therapy...
Dec 07, 2020 04:05 pm ET
uniQure Announces Two-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated clinical data on the three patients treated in uniQure’s ongoing Phase IIb study of...
Dec 02, 2020 07:05 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in December
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that its participation in the following upcoming virtual investor and scientific conferences: •...
Nov 30, 2020 07:05 am ET
uniQure Announces Multiple Presentations and Investor Webcast on Hemophilia B Gene Therapy Program at the 62nd American Society of Hematology (ASH) Annual Meeting
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that Steven Pipe, M.D., professor of pediatrics and pathology and pediatric medical director of...
Nov 19, 2020 09:10 am ET
uniQure Announces Positive Top-Line Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced positive top-line data from its pivotal, Phase III HOPE-B gene therapy trial of etranacogene...
Nov 04, 2020 10:46 am ET
uniQure Announces Clinical Data Presentations at the 62nd American Society of Hematology (ASH) Annual Meeting
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation and three poster presentations,...
Nov 04, 2020 07:05 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in November
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that members of uniQure’s management team including Matt Kapusta, chief executive officer,...
Oct 27, 2020 07:05 am ET
uniQure Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2020 and highlighted recent progress across its...
Oct 13, 2020 07:05 am ET
uniQure Announces Enrollment of Next Two Patients in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that two additional patient procedures have been completed in the Phase I/II clinical trial of...
Sep 30, 2020 07:05 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in October
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that Matt Kapusta, chief executive officer at uniQure, Maria Cantor, chief communications...
Sep 25, 2020 07:05 am ET
uniQure Announces Recommendations from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing the Phase I/II clinical trial...
Sep 03, 2020 07:05 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in September
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that Matt Kapusta, chief executive officer at uniQure, Maria Cantor, senior vice president of...
Aug 26, 2020 07:05 am ET
uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Ricardo Dolmetsch, Ph.D., as President, Research and Development, effective...
Jul 30, 2020 07:05 am ET
uniQure Announces Second Quarter 2020 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2020 and highlighted recent progress across its...
Jun 24, 2020 06:28 pm ET
CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure
KING OF PRUSSIA, Pa., June 24, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire exclusive global license rights to commercialize an adeno-associated virus (AAV) gene therapy program, AMT-061 (etranacogene dezaparvovec), for the treatment of hemophilia B from uniQure (NASDAQ: QURE), a leading gene therapy company. The AMT-061 program, currently in Phase 3 clinical trials, could be one of the first gene therapies to provide potentially long-term benefits to patients with hemophilia B.
Jun 24, 2020 04:05 pm ET
uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that uniQure and CSL Behring have entered into a licensing agreement providing CSL Behring with...
Jun 19, 2020 07:05 am ET
uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first two patients in the Phase I/II clinical trial of AMT-130 for the treatment of...
Jun 17, 2020 04:05 pm ET
uniQure Announces the Appointment of Leonard E. Post, Ph.D. to its Board of Directors
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Leonard E. Post, Ph.D. to its Board of Directors. Dr. Post, who will also...
Jun 15, 2020 07:05 am ET
uniQure Announces Change for its 2020 Annual General Meeting of Shareholders
uniQure N.V. (NASDAQ: QURE) announced today a change to the location and format of its 2020 Annual General Meeting of Shareholders (the “2020 Annual Meeting”). In light of the continuing coronavirus (COVID-19) pandemic and public health concerns,...
May 14, 2020 07:00 am ET
uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, presented new preclinical data on its gene therapy candidates AMT-150 for Spinocerebellar Ataxia type 3, AMT-190...
Apr 29, 2020 07:00 am ET
uniQure Announces First Quarter 2020 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2020 and highlighted recent progress across its...
Apr 28, 2020 04:51 pm ET
uniQure Announces Significant Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 22 data presentations, of which five are oral presentations, will be delivered at the...
Apr 17, 2020 07:00 am ET
uniQure Announces the Nomination of Leonard E. Post, Ph.D. to its Board of Directors
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the nomination of Leonard E. Post, Ph.D. to stand for election to its Board of Directors. Dr....
Mar 30, 2020 07:00 am ET
uniQure to Participate in Multiple Upcoming Investor Conferences in April
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming investor events in April: Stifel CNS Day...
Mar 26, 2020 07:00 am ET
uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia B
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced it has achieved the targeted dosing of patients in the HOPE-B pivotal trial of etranacogene...
Mar 03, 2020 07:00 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in March
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in March: Cowen 40th Annual...
Mar 02, 2020 04:05 pm ET
uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic Promoters
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, and Gen-X, a spin-off company from the Netherlands Cancer Institute, today announced that they have signed an...
Mar 02, 2020 04:05 pm ET
uniQure Announces 2019 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for 2019 and highlighted recent progress across its business. “The past...
Feb 27, 2020 07:00 am ET
uniQure Presents Multiple New Preclinical Data on AMT-130 at the CHDI’s 15th Annual Huntington’s Disease Therapeutics Conference
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the presentation of multiple new preclinical data on AMT-130, its investigational AAV gene...
Feb 04, 2020 07:00 am ET
uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that seven presentations, of which one is an oral presentation, will be delivered at the upcoming...
Jan 31, 2020 07:00 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in February
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in February: 13th Annual Congress...
Dec 19, 2019 07:00 am ET
uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington’s Disease Supporting Non-Selective HTT-Lowering Approach
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced two publications of preclinical data from its gene therapy candidate AMT-130 in...
Dec 08, 2019 04:00 pm ET
uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated clinical data on the three patients treated in uniQure’s ongoing Phase IIb study of...
Dec 02, 2019 07:00 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in December
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in December: Piper Jaffray...
Nov 06, 2019 09:16 am ET
uniQure Announces Clinical Data Presentations at the 61st American Society of Hematology (ASH) Annual Meeting
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that six data presentations will be delivered at the 61st American Society of Hematology...
Nov 05, 2019 07:00 am ET
uniQure Announces the Allowance of New Patent Providing Further Protection of the Padua and Padua-Related Variants of Factor IX in Gene Therapy
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 10,465,180. This patent...
Nov 01, 2019 07:00 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in November
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in November: Huntington Study...
Oct 31, 2019 07:00 am ET
uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced the publication of 26-week interim data from the ongoing Phase IIb clinical trial of...
Oct 28, 2019 07:00 am ET
uniQure Announces Third Quarter 2019 Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2019 and highlighted recent progress across its...
Sep 27, 2019 07:00 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in October
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in October: 2019 Cantor Global...
Sep 05, 2019 08:39 pm ET
uniQure Announces Pricing of its Public Offering
uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs today announced the pricing of its underwritten public offering of 4,891,305 of its ordinary shares at a...
Sep 04, 2019 04:02 pm ET
uniQure Announces Proposed Public Offering
uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it has commenced an underwritten public offering of $200 million of its ordinary...
Sep 03, 2019 07:00 am ET
uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that the planned enrollment of 56 patients has been achieved in the HOPE-B pivotal trial of...
Aug 30, 2019 07:00 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences in September
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in September: Citi 14th Annual...
Aug 20, 2019 07:00 am ET
uniQure Announces Leadership Promotions and Executive Transition
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the promotions of Sander van Deventer, M.D., Ph.D., to Executive Vice President, Research and...
Jul 29, 2019 07:18 am ET
uniQure Announces Second Quarter 2019 Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2019 and highlighted recent progress across its...
Jul 26, 2019 07:00 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences: 2019 Wells Fargo Biotech...
Jul 06, 2019 07:00 am ET
uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated clinical data on the three patients treated in the Company’s ongoing Phase IIb study of...
Jun 21, 2019 07:00 am ET
uniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that five data presentations, of which three are oral presentations, will be featured at the...
May 31, 2019 07:00 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in June: Gordon Research...
May 22, 2019 07:00 am ET
uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the issuance of two new patents covering AMT-130, the Company’s gene therapy candidate for the...
May 10, 2019 08:00 am ET
uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced updated clinical data in patients treated in the Company’s ongoing Phase IIb study of...
May 07, 2019 07:00 am ET
uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, will today present preclinical data on its gene therapy candidate, AMT-150, for the treatment of Spinocerebellar...
May 02, 2019 07:00 am ET
uniQure Announces New Preclinical Data in Hemophilia A and Fabry Disease in Oral Presentations at the 22nd ASGCT Annual Meeting
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, will present today new preclinical data on its gene therapy candidates AMT-180 for the treatment of hemophilia A...
May 01, 2019 07:00 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in May: 2019 American Academy of...
Apr 29, 2019 07:00 am ET
uniQure Announces First Quarter 2019 Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2019 and highlighted recent progress across its...
Apr 16, 2019 07:25 am ET
Investor Expectations to Drive Momentum within uniQure N.V., Aflac, ANI Pharmaceuticals, MaxLinear, ZAGG, and Aqua America — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of uniQure N.V. (NASDAQ:QURE), Aflac Incorporated (NYSE:AFL), ANI...
Apr 15, 2019 12:15 pm ET
uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that six data presentations, of which three are oral presentations, will be delivered at the...
Apr 08, 2019 07:00 am ET
uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AMT-130,...
Mar 29, 2019 07:00 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in April: Stifel First Annual CNS...
Mar 01, 2019 07:00 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in March: Leerink Global Health...
Feb 28, 2019 07:00 am ET
uniQure Announces 2018 Financial Results and Highlights Recent Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for 2018 and highlighted recent progress across its business. "2018 was a...
Feb 27, 2019 07:00 am ET
uniQure Presents New Preclinical Data on AMT-130 at the CHDI’s 14th Annual Huntington’s Disease Therapeutics Conference
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today presented new preclinical data on AMT-130, its gene therapy candidate for the treatment of Huntington’s...
Feb 22, 2019 07:45 am ET
Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Graphic Packaging Holding Company (NYSE:GPK), Vulcan Materials Company...
Feb 15, 2019 07:24 am ET
uniQure Announces Publications on AAV Gene Therapy Approach to Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) in the Journal Molecular Therapy Nucleic Acids
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced two recent online publications of preclinical studies showing significant silencing, or...
Feb 08, 2019 07:00 am ET
uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced updated clinical data in patients treated in the Company’s ongoing Phase IIb study of...
Feb 04, 2019 07:00 am ET
uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it treated the first patient in its HOPE-B pivotal trial of AMT-061, an...
Jan 30, 2019 07:00 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in February: 12th Annual...
Jan 22, 2019 07:00 am ET
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntington’s Disease
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s...
Dec 03, 2018 07:00 am ET
uniQure Announces Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 and Confirms Dose for AMT-061 Pivotal Study in Hemophilia B
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated results from its ongoing Phase I/II trial of AMT-060, and provided an update on AMT-061,...
Nov 30, 2018 08:00 am ET
Analysis: Positioning to Benefit within Vivint Solar, uniQure N.V, Internap, Intuit, WideOpenWest, and Deere — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Vivint Solar, Inc. (NYSE:VSLR), uniQure N.V. (NASDAQ:QURE), Internap...
Nov 19, 2018 12:15 pm ET
uniQure Highlights Pipeline Expansion and Advancements in Technology at Research & Development Day
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the expansion of its research pipeline with novel AAV gene therapy approaches to treating...
Nov 15, 2018 07:00 am ET
uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced initial clinical data in patients treated in the Company’s Phase IIb dose-confirmation...
Nov 06, 2018 07:00 am ET
uniQure Announces Third Quarter 2018 Financial Results and Highlights Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2018 and highlighted recent progress across its...
Nov 05, 2018 07:00 am ET
uniQure to Host Research & Development Day on Monday, November 19 in New York City
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will host a Research & Development Day on Monday, November 19, 2018 in New York City,...
Oct 31, 2018 07:00 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in November: World Orphan Drug...
Oct 23, 2018 07:45 am ET
Report: Exploring Fundamental Drivers Behind The Home Depot, uniQure N.V, Catalent, Apple, BioTime, and PDL BioPharma — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Home Depot, Inc. (NYSE:HD), uniQure N.V. (NASDAQ:QURE), Catalent, Inc....
Oct 18, 2018 06:55 am ET
uniQure Announces Development of a Highly Potent, Next-Generation Promoter for Liver-Directed Gene Therapies
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today presented non-clinical data demonstrating that a next-generation synthetic promoter developed for...
Oct 17, 2018 07:00 am ET
uniQure Presents New Data Demonstrating Its Large-Scale Manufacturing Capabilities at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today presented new data demonstrating its ability to manufacture gene therapies using a 500 liter...
Oct 16, 2018 07:00 am ET
uniQure Announces Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that five data presentations, including one oral presentation, will be delivered at the...
Sep 28, 2018 07:00 am ET
uniQure to Participate in Multiple Upcoming Industry Conferences
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in October: Leerink Partners...
Sep 24, 2018 07:00 am ET
uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs,  today announced that the third patient has been treated in the Company’s Phase IIb dose-confirmation...
Sep 10, 2018 06:00 am ET
Achillion Appoints Paul Firuta Chief Operating Officer
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Paul Firuta to the position of Executive Vice President and Chief Operating Officer effective immediately. Mr. Firuta, with 27 years of experience successfully...
Aug 30, 2018 07:00 am ET
uniQure to Participate at Multiple Upcoming Conferences
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in September: • Wells Fargo...
Aug 23, 2018 07:00 am ET
uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it has treated the first patient in its Phase IIb dose-confirmation study of AMT-061,...
Aug 21, 2018 08:30 am ET
Report: Exploring Fundamental Drivers Behind Oaktree Specialty Lending, uniQure N.V, Mercury, Akebia Therapeutics, Mitel Networks, and Greenlight Capital Re — New Horizons, Emerging Trends, and Upcomi
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oaktree Specialty Lending Corp. (NASDAQ:OCSL), uniQure N.V. (NASDAQ:QURE),...
Aug 08, 2018 07:00 am ET
uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2018 and highlighted recent progress across its...
Jun 28, 2018 07:00 am ET
uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it has enrolled its first patient in the Phase III HOPE-B pivotal study of AMT-061, an...
Jun 13, 2018 07:00 am ET
uniQure Announces New Appointments to its Board of Directors
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Robert Gut, M.D., Ph.D. and David Meek to its Board of Directors. Dr. Gut and...
Jun 06, 2018 08:30 am ET
Analysis: Positioning to Benefit within Willis Towers Watson Public, MyoKardia, Texas Capital Bancshares, uniQure N.V, Retail Opportunity Investments, and GDS Holdings Limited — Research Highlights Gr
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Willis Towers Watson Public Limited Company (NASDAQ:WLTW), MyoKardia, Inc....
May 29, 2018 07:00 am ET
uniQure Announces the Issuance of New Patents Providing Broad Protection of the Padua Variant of Factor IX in Gene Therapy
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, such as hemophilia B, Huntington's disease and congestive heart failure, today announced that the U.S....
May 21, 2018 07:00 am ET
uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, presented data showing successful liver transduction with the AAV5 vector in both non-human primates and humans...
May 18, 2018 07:00 am ET
uniQure Presents Preclinical Data Demonstrating Advances in the Distribution of Gene Therapy
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, presented preclinical data in three poster presentations at this week’s American Society of Gene and Cell Therapy...
May 07, 2018 11:47 am ET
uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares
uniQure N.V. (Nasdaq:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, such as hemophilia B, Huntington’s disease and congestive heart failure, today announced the closing of its...
May 02, 2018 07:32 pm ET
uniQure Announces Pricing of its Public Offering
uniQure N.V. (Nasdaq:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, such as hemophilia B, Huntington’s disease and congestive heart failure, today announced the pricing of its...
May 01, 2018 04:04 pm ET
uniQure Announces Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 01, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, such as hemophilia B, Huntington’s disease and congestive...
Apr 30, 2018 12:00 pm ET
uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)
New Data Further Demonstrating Favorable Immunogenicity Profile of AAV5 to be Featured in Oral Presentation
Apr 30, 2018 07:05 am ET
uniQure Announces First Quarter 2018 Financial Results and Highlights Company Progress
~ Patient enrollment expected to begin ahead of schedule in dose-confirmation study for AMT-061 and pivotal study on track to commence in third quarter of 2018
Apr 27, 2018 07:00 am ET
uniQure Announces to Present at Multiple Conferences in May
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 27, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that it will be featured in multiple presentations at upcoming medical and scientific conferences in...
Apr 25, 2018 04:15 pm ET
uniQure Delivers Oral Presentation on Broad Set of Preclinical Data on AMT-130 in Huntington’s Disease at the 2018 American Academy of Neurology Annual Meeting
~ Mutant Huntingtin Protein Reduced by a Median of 68% in the Deep Structures of the Brain and a Median of 47% in the Frontal Cortex at 6 Months in a Large Diseased Animal Model ~  
Apr 09, 2018 07:35 am ET
Report: Developing Opportunities within Consol Energy, 51job, MakeMyTrip, LyondellBasell Industries N.V, Golden Ocean Group, and uniQure N.V — Future Expectations, Projections Moving into 2018
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Consol Energy Inc. (NYSE:CEIX), 51job, Inc....
Mar 16, 2018 08:25 am ET
Report: Developing Opportunities within Itau Unibanco Banco Holding SA, NantHealth, Southern First Bancshares, uniQure N.V., Ascendis Pharma A/S, and National General — Future Expectations, Projection
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Itau Unibanco Banco Holding SA (NYSE:ITUB),...
Mar 14, 2018 07:00 am ET
uniQure Announces 2017 Financial Results and Recent Company Progress
~ On Track to Begin Pivotal Study of AMT-061 in Hemophilia B in Q3 2018
Feb 27, 2018 07:00 am ET
uniQure to Participate in Multiple Conferences in March
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 27, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that it will be featured in multiple presentations at upcoming medical, scientific and investor conferences...
Feb 01, 2018 07:00 am ET
uniQure to Participate in Multiple Conferences in February
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 01, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that members of company management or principal investigators will participate in upcoming business, medical and...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.